IL-1β binding antibodies and binding fragments thereof

Details IL-1β binding antibodies and binding fragments thereof IL-1β binding antibodies and binding fragments thereof

2009-05-11

2010-06-29

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C530S387100, C530S388100

Reexamination Certificate

active

07744866

ABSTRACT:
An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

REFERENCES:
patent: 4762914 (1988-08-01), Auron et al.
patent: 4766069 (1988-08-01), Auron et al.
patent: 4772685 (1988-09-01), Schmidt et al.
patent: 4935343 (1990-06-01), Allison et al.
patent: 5001057 (1991-03-01), Auron et al.
patent: 5077219 (1991-12-01), Auron et al.
patent: 5122459 (1992-06-01), Conlon et al.
patent: 5286847 (1994-02-01), Gehrke et al.
patent: 5348858 (1994-09-01), Uetsuki et al.
patent: 5474899 (1995-12-01), Lisi
patent: 5484887 (1996-01-01), Kronheim et al.
patent: 5510462 (1996-04-01), Auron et al.
patent: 5658570 (1997-08-01), Newman et al.
patent: 5681933 (1997-10-01), Auron et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5789185 (1998-08-01), Lisi
patent: 5869619 (1999-02-01), Studnicka
patent: 5885793 (1999-03-01), Griffiths
patent: 5959085 (1999-09-01), Garrone et al.
patent: 6899878 (2005-05-01), Graham et al.
patent: 7531166 (2009-05-01), Masat et al.
patent: 2003/0022869 (2003-01-01), Wiemer et al.
patent: 2003/0026806 (2003-02-01), Witte et al.
patent: 2003/0124617 (2003-07-01), Gram et al.
patent: 2003/0166069 (2003-09-01), Welcher et al.
patent: 2004/0023869 (2004-02-01), Sims et al.
patent: 2004/0063913 (2004-04-01), Gram et al.
patent: 2005/0084493 (2005-04-01), Witte
patent: 2005/0152850 (2005-07-01), Engebretson
patent: 2005/0186615 (2005-08-01), Lin et al.
patent: 2005/0256197 (2005-11-01), Engebretson
patent: 2006/0094663 (2006-05-01), Chemtob
patent: 2009/0060918 (2009-03-01), Masat et al.
patent: 2009/0060923 (2009-03-01), Masat et al.
patent: 0267611 (1993-05-01), None
patent: 0161 901 (1993-12-01), None
patent: 0364778 (1996-03-01), None
patent: 0569687 (2002-08-01), None
patent: 95/01997 (1995-01-01), None
patent: 0216436 (2002-02-01), None
patent: 0216436 (2002-02-01), None
patent: 03/010282 (2003-02-01), None
patent: 03/034984 (2003-05-01), None
patent: 03/073982 (2003-09-01), None
patent: 2004002512 (2004-01-01), None
patent: 2004/067568 (2004-08-01), None
patent: 2004/072116 (2004-08-01), None
patent: 2005019259 (2005-03-01), None
patent: 2005084696 (2005-09-01), None
patent: 2006/081139 (2006-08-01), None
patent: 2007002261 (2007-01-01), None
patent: 2004022718 (2008-06-01), None
Fantuzzi, et al., Effect of endotoxin in IL-1beta deficient mice, Journal of Immunology 157:291-96 (1996).
Fantuzzi, et al., Response to local inflammation of IL-1beta converting enzyme-deficient mice, J Immunology 158:1818-824 (1997).
Fantuzzi, et al., Physiological and cytokine responses in interleukin-1beta deficient mice after zymosan-induced inflammation, American Journal of Physiology (1997).
Feingold, et al., Effect of Interleukin-1 on Lipid Metabolism in the Rat. Similarities to and differences from tumor necrosis factor, Arteriosclerosis and Thrombosis and Vascular Biology. Am Heart Assoc.11(3):495-500 (1991).
Firestein GS. Rheumatoid Arthritis. ACPMedicine. 15(11):1-18 (2007).
Fredericks et al., Identification of potent human anti-IL-1 RI antagonist antibodies. Protein Eng. Des. Sel. 17:95-106 (2004).
Garrone et al., Generation and characterization of a human monoclonal autoantibody that acts as a high affinity interleukin-1 alpha specific inhibitor. Mol. Immunol. 33:649-658 (1996).
Geiger T, et al. Neutralization of interleukin-1 beta activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin Exp Rheumatol. 11(5): 515-22 (1993).
Genta, et al., Systemic Rheumatoid Vasculitis: A Review, Semin Arthritis Rheum 36:88-98 (2006).
Gershenwald et al., Interleukin 1 receptor blockade attenuates the host inflammatory response. Proc. Natl. Acad. Sci. USA 87:4966-4970 (1990).
Goupille P., et al., Safety and efficacy of intra-articular injection of IL-1 ra (IL-1 receptor antagonist) in patients with painful osteroarthritis of the knee: a multicenter, double blind study. Arthritis and Rheumatism 48(9) (2003).
Gracie, et al., A proinflammatory role for IL-1Beta in rheumatoid arthritis. J. Clin, Invest. 104(10): 1393-401 (1999).
Greenberg et al., Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes, Eur J. Clin. Invest. 32 Suppl.3:24-34 (2002).
Grundy, S.M., Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds, J. Am. Coil. Cardiol. 47:1093-1000 (2006).
Grunstein, et al., Autocrine cytokine signaling mediates effects of rhinovirus on airway responsiveness. Am. J. Physiol Lung Cell Mol. Physiol. 278: L1146-53 (2000).
Grutter, MG, et al., A mutational analysis of receptor binding sites of interleukin-1Beta differences in binding of human interleukin-1Beta muteins to human and mouse receptors. Protein Eng. 7:663-671 (1994).
Gruver, D., Living With Rheumatoid Arthritis: Unmet Needs (2004).
Guerne, et al., Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis and Rheumatism 32(11):1443-452 (1989).
Guo et al.,. Fluorescence resonance energy transfer reveals interleukin (IL)-1-dependent aggregation of IL-1 type I receptors that correlates with receptor activation, J. Biol. Chem. 270:27562-27568 (1995).
Gustafsson, et al., Cytokine, elastase and oxygen radical release by Fusobacterium nucleatum-activated leukocytes: a possible pathogenic factor in periodontitis. J. Clin, Periodontol. 27(10): 756-62 (2000).
Hallegua and Weisman, Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases, Ann Rheum Dis 61:960-967 (2002).
Harada et al., Promotion of spontaneous diabetes in non-obese diabetes-prone mice by cyclophosphamide, Diabetologia 27:604-606 (1984).
Haraoui et al., Biologic agents in the treatment of rheumatoid arthritis. Curr. Pharm. Biotechnol. 1:217-233 (2000).
Harris Ed, et al., Overview of the management of rheumatoid arthritis. UptoDate®. Feb. 4, 2008.
Hawkins, PN et ai, Spectrum of clinical features in muckle-wells syndrome and response to anakinra. Arthritis and Rheumatism. 50: 607-612 (2004).
Hedges, et al., Mitogen-Activated Protein Kinases Regulate Cytokine Gene Expression in Human Airway Myocytes. Am. J. Respir. Cell Mol. Bio. 23: 86-94 (2000).
Herzbeck et al., Functional and molecular characterization of a monoclonal antibody against the 165-186 peptide of human IL-1 beta. Scand. J. Immunol. 30:549-562 (1989).
Hochberg MC., Racial differences in the incidence of gout. The role of hypertension. Arthritis and Rheumatism 38:628-632 (1995).
Hoffman, et al., Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist, Lancet 364:1779-85 (2004).
Hull, et al., The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations, Curr Opin Rheumatol 15:61-69 (2003).
Hultin, et al., Microbiological findings and host response in patients with peri-implantitis. Clin. Oral Implants Res. 13: 349-56 (2002).
Inoue K, Masuko-Hongo K., Okamoto M., Nishiota K., Efficacy of daily compared to intermittent administration of IL-1 Ra for protection against bone and cartilage destruction in collagen-challenged mice. Clin Exp Rheumatol. 21(1):33-9 (2003).
Jackson et al., In vitro antibody maturation: Improvement of a high affinity, neutralizing antibody against IL-113. J. Immunol. 154:3310-3319 (1995).
Jacques, C., et al.. The role of IL-1 and IL-Ra in joint inflammation and cartilage degradation. Vitam Horm 74:371-404 (2006).
Jager, et al., Interleukin-1 Beta-Induced Insulin Resistance in Adipocytes Through Down-Regulation of Insulin Receptor Substrate-1 Expression, Endocrinology 148:241-251 (2007).
Johnson, et al, “Inhibition of vagally me

Affiliated with

Also associated with

Rating

IL-1β binding antibodies and binding fragments thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with IL-1β binding antibodies and binding fragments thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and IL-1β binding antibodies and binding fragments thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4221821